For companies, the Physics on Demand programme offers the opportunity to strengthen their R&D power with innovations and facilities of the Amsterdam universities. By building collaborative partnerships, specific scientific expertise, equipment and state-of-the-art research facilities will be made available.
In addition, our Research Facilities database provides access to high-end equipment, research instruments and expertise for R&D activities.
If you are interested, please reach out to one of our business developers.
For researchers seeking to collaborate with industrial partners, the IXAnext program provides the Physics2Market Grant. This grant encourages knowledge utilisation, by helping researchers validate physics-related research. This is helpful when companies need further proof that a science-based concept or technique can indeed have a practical application before they agree to collaborate.
This financial instrument is closed for applications. The total available budget of €250,000 has been spent.
The IXAnext valorisation programme is made possible with a contribution of the City of Amsterdam.
Amsterdam researchers have secured Biotech Booster funding for a total of six projects, that include a promising cancer treatment, a new diagnostic method for Alzheimer’s Disease, an implant helping blindness, lab innovation in biotechnology, and a nutritional intervention for mental health. The researchers will develop a solid business case for their innovations in the time […]
NewsPULSE Sport, a start-up from the Demonstrator Lab, has reached a significant milestone by winning the prestigious 14th Dutch Sports Innovation Award. The company’s flagship product, a cutting-edge athlete management system, integrates advanced software and artificial intelligence to revolutionize athlete health and performance monitoring. About the Innovation PULSE Sport’s athlete management system provides a holistic […]
NewsVU-AMS is on a mission to revolutionize how we understand and manage stress-related health issues. Now an official VU spin-off, there are big plans for clinical applications. Founder of VU AMS Martin Gevonden explains: “We offer researchers autonomic biomarkers that are valid, reliable and easy to use, without getting under the skin.” After thriving in […]
News